Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI and Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma
NCT07676877Phase 1Recruiting
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL). Primary endpoints: Dose-limiting toxicities and Maximum tolerated dose or recommended phase 2 dose. Planned start Dec 2026; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07676877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07676877.